Investigational Drug Details
| Drug ID: | D533 |
| Drug Name: | Lisinopril |
| Synonyms: | Prinivil; Qbrelis; Zestoretic; Zestril |
| Type: | Chemical drug |
| DrugBank ID: | DB00722 |
| DrugBank Description: | Lisinopril is an ACE inhibitor used to treat hypertension, heart failure, and acute myocardial infarction. |
| PubChem ID: | -- |
| CasNo: | 76547-98-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O |
| Structure: |
|
| InChiKey: | RLAWWYSOJDYHDC-BZSNNMDCSA-N |
| Molecular Weight: | 405.4879 |
| DrugBank Targets: | Angiotensin-converting enzyme inhibitor; Renin inhibitor |
| DrugBank MoA: | Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption. This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation. Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II. This action prevents myocyte hypertrophy and vascular smooth muscle cell proliferation seen in untreated patients. Increased levels of bradykinin also exhibit vasodilating effects for patients taking ACEIs. Lisinopril also inhibits renin's conversion of angiotensin to angiotensin I. |
| DrugBank Pharmacology: | Lisinopril is an angiotensin converting enzyme inhibitor used to treat hypertension, heart failure, and myocardial infarction. Lisinopril is not a prodrug, and functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. It has a wide therapeutic index and a long duration of action as patients are generally given 10-80mg daily. |
| DrugBank Indication: | Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension. |
| Targets: | ACE inhibitor |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (NCT04550481) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0411 | NCT04550481 | Phase 2 | Recruiting | No Results Available | 15/09/2020 | 21 February 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A06965 | 32684739 | World J Gastroenterol | Medications in type-2 diabetics and their association with liver fibrosis. | Details |
| A12474 | 30431378 | Curr Med Res Opin | Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. | Details |
| A19678 | 28294798 | Kardiologiia | [Safety and Efficacy of Amlodipine, Lisinopril and Rosuvastatin Therapy in Patients With Metabolic Syndrome and Nonalcoholic Fatty Liver Disease]. | Details |